[Skip to Content]
[Skip to Content Landing]
January 15, 1982

Evaluation of Bone Marrow Toxic Reaction in Patients Treated With Allopurinol

Author Affiliations

From Tufts University, Boston (Dr Stolbach); the Sidney Farber Cancer Institute, Boston (Dr Begg); the University of Rochester Cancer Center, Rochester, NY (Dr Bennett); the Mayo Clinic, Rochester, Minn (Dr Silverstein); the University of Pretoria, Pretoria, South Africa (Dr Falkson); the American Oncologic Hospital, Philadelphia (Dr Harris); and the Hospital of the University of Pennsylvania, Philadelphia (Dr Glick).

JAMA. 1982;247(3):334-336. doi:10.1001/jama.1982.03320280054030

To evaluate possible bone marrow toxic reaction related to allopurinol administration, 143 patients with malignant lymphoma were randomized to receive allopurinol for either three or six cycles of chemotherapy. There was no significant difference of nadir WBC or platelet counts. This trial failed to confirm an earlier study that suggested that allopurinol increased the marrow toxic reaction of cytotoxic chemotherapy.

(JAMA 1982;247:334-336)